VRCDF (Verici Dx) Buildings And Improvements: $1.29 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Verici Dx Buildings And Improvements?

Verici Dx VRCDF -60.53% Buildings And Improvements is $1.29 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Verici Dx's quarterly buildings and improvements declined from Dec. 2024 ($1.29 Mil) to Jun. 2025 ($0.00 Mil) but then increased from Jun. 2025 ($0.00 Mil) to Dec. 2025 ($1.29 Mil).

Verici Dx's annual buildings and improvements stayed the same from Dec. 2023 ($1.29 Mil) to Dec. 2024 ($1.29 Mil) and stayed the same from Dec. 2024 ($1.29 Mil) to Dec. 2025 ($1.29 Mil).

Verici Dx Buildings And Improvements Historical Data

* Premium members only.

The historical data trend for Verici Dx's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verici Dx Buildings And Improvements Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buildings And Improvements
Get a 7-Day Free Trial 0.00 1.29 1.29 1.29 1.29

Verici Dx Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.29 0.00 1.29 0.00 1.29

Verici Dx Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.

What does a Buildings And Improvements of $1.29 Mil mean?
Verici Dx (VRCDF) has a Buildings And Improvements of $1.29 Mil as of Dec. 2025. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Verici Dx and its competitors.
Is Verici Dx's Buildings And Improvements too high?
Verici Dx's current Buildings And Improvements is $1.29 Mil.
How does Verici Dx's Buildings And Improvements compare to TMO and DHR?
Verici Dx's Buildings And Improvements of $1.29 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buildings And Improvements for a Medical Diagnostics & Research company?
A good Buildings And Improvements depends on the Medical Diagnostics & Research industry context. However, Buildings And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buildings And Improvements mean?
A high Buildings And Improvements can signal that a stock is expensive relative to its fundamentals. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Verici Dx and its competitors. Verici Dx's current Buildings And Improvements is $1.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (VRCDF) has a current Buildings And Improvements of $1.29 Mil. The current Buildings And Improvements is $1.29 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buildings And Improvements calculated?
Buildings And Improvements is calculated from a company's financial statements. For Verici Dx (VRCDF), the current Buildings And Improvements is $1.29 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Verici Dx Business Description

Other Exchanges VRCI:UK63V:Germany
Address 19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.